In a stunning blow to corporate giant Johnson & Johnson, a California jury has awarded a groundbreaking $40 million to two women who developed ovarian cancer after decades of using the company’s talc-based baby powder. But here’s where it gets controversial: this verdict isn’t just about compensation—it’s a damning indictment of J&J’s alleged decades-long concealment of asbestos contamination in their products. And this is the part most people miss: the trial revealed internal documents from the 1970s showing J&J knowingly put public health at risk. Could this be the tipping point in holding corporations accountable for prioritizing profits over people’s lives?
The Los Angeles Superior Court’s decision marks the first plaintiff victory in a talc-ovarian cancer case since 2021, following J&J’s three failed attempts to evade accountability through bankruptcy filings. The $40 million award goes to plaintiffs Monica Kent and Deborah Schultz, along with her husband, Dr. Albert Schultz, who argued that J&J’s talc products were a direct cause of their cancers. This case is just the beginning—it’s the first of at least 10 trials expected through 2026, with thousands of women still awaiting their day in court.
Former FDA Commissioner Dr. David Kessler’s testimony was a game-changer. He revealed that J&J’s concealment of asbestos evidence spanned over five decades, a revelation that left jurors stunned. “These women trusted J&J with their health, only to be betrayed by a company that knew the risks but chose silence,” said Andy Birchfield, lead trial counsel for the plaintiffs. The scientific evidence presented was equally compelling: peer-reviewed studies showed that frequent genital talc use increases ovarian cancer risk by at least 50%, with long-term use potentially doubling that risk.
Here’s the bold truth: J&J’s legal maneuvers and corporate intimidation tactics failed to sway the jury. Leigh O’Dell, Co-Lead of the MDL Plaintiffs’ Steering Committee, stated, “This verdict sends an unmistakable message—justice will prevail, no matter how hard corporations try to evade it.” But the question remains: will this verdict spark broader accountability, or will corporations continue to prioritize profits over public health?
This case also highlights the resilience of the plaintiffs. Dan Robinson, representing the Schultz family, praised their courage in standing up to one of the world’s most powerful corporations. Meanwhile, over 70,000 claims in federal multidistrict litigation in New Jersey are set for bellwether trials next year, alongside additional trials in California, New Jersey, and Pennsylvania.
As we reflect on this landmark verdict, it’s impossible not to ask: How many more lives could have been saved if J&J had acted responsibly? And what does this mean for corporate accountability moving forward? Share your thoughts in the comments—this conversation is far from over.
